FIELD: biotechnology.
SUBSTANCE: invention relates to novel antigen-binding molecules. Invention discloses a HER2-specific antibody containing 4-1BBL-trimer.
EFFECT: invention can be used in medicine for treating cancer, including in combination with T-cell activating CD3-bispecific antibodies.
16 cl, 5 ex, 13 tbl, 16 dwg
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
PSEUDO-FAB BASED MULTISPECIFIC BINDING PROTEINS | 2019 |
|
RU2820254C2 |
DISPLAY OF AN INTEGRAL MEMBRANE PROTEIN ON EXTRACELLULAR ENVELOPED POXVIRUS VIRIONS | 2017 |
|
RU2759846C2 |
AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR TREATING BILE DUCT CANCER | 2019 |
|
RU2819802C2 |
POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
Authors
Dates
2024-03-15—Published
2019-04-12—Filed